Phio Pharmaceuticals (PHIO) Other Working Capital Changes (2020 - 2024)
Phio Pharmaceuticals' (PHIO) quarterly Other Working Capital Changes came in at -$35000.0 in Q1 2024, down 9.38% YoY from -$38620.7 in Q2 2023, and little changed on a QoQ basis from -$35000.0 in Q4 2023.
Phio Pharmaceuticals (PHIO) Other Working Capital Changes (2020 - 2024) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 5 years of Other Working Capital Changes data on file, last reported at -$35000.0 in Q1 2024.
- Quarterly Other Working Capital Changes fell 9.38% year-over-year to -$35000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$35000.0 (up 74.07% YoY) and the FY2024 annual result came in at -$35000.0, up 74.07% from the prior year.
- Other Working Capital Changes was little changed at -$35000.0 in Q1 2024, from -$35000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $538000.0 in Q1 2022 to a low of -$778000.0 in Q3 2022.
- A 5-year average of -$16235.3 and a median of -$74000.0 in 2026 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2021 — Other Working Capital Changes increased 29.63% — and 2022, when it slumped 68.42%.
- Tracing PHIO's Other Working Capital Changes over 5 years: stood at -$27000.0 in 2020, then advanced by 29.63% to -$19000.0 in 2021, then tumbled by 68.42% to -$32000.0 in 2022, then slipped by 9.38% to -$35000.0 in 2023, then changed by 0.0% to -$35000.0 in 2024.
- The last three Other Working Capital Changes figures came in at -$35000.0 (Q1 2024), -$35000.0 (Q4 2023), and -$34000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -35,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Dec 31, 2023 | -35,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -34,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -32,000.00 |
| Dec 31, 2022 | -32,000.00 |
| Dec 31, 2022 | -32,000.00 |
| Sep 30, 2022 | -32,000.00 |
| Sep 30, 2022 | -32,000.00 |